Skip to main content
. 2020 Apr;9(4):2210–2219. doi: 10.21037/tcr.2020.03.48

Figure 4.

Figure 4

Kaplan-Meier estimated of tumor recurrence-free survival in ERBT vs. TURBT group. (A) Recurrence-free survival for low-risk patients. (B) Recurrence-free survival for intermediate-risk patients. (C) Recurrence-free survival for high-risk patients. (D) Recurrence-free survival for all patients.